Abstract
Among the many variables affecting transmission and pathogenesis of the human immunodeficiency virus type 1(HIV-1), the effects of HIV subtypes, or clades, on disease progression remain unclear. Although debated, some studies have found that the variable env and pol sequences of different subtypes of HIV-1 may endow some subtypes with greater degrees of cell tropism, virulence, and drug resistance, which may lead to differences in overall disease progression. HIV-associated dementia (HAD) appears to be associated with viral diversity and markers of immune activation. Africa has the highest prevalence of HIV, largest viral diversity, and is where clade recombination occurs most frequently. All of these factors would suggest that HAD would pose the largest threat in this region of the world. Although investigations into the effects of different subtypes on overall disease progression are well documented, few have looked into the effects of subtypes on neurological disease progression. This review highlights the need for more international research involving the neurological effects and especially the clinical presentation of dementia for the entire range of the group M HIV-1 subtypes.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Abebe A, Demissie D, Goudsmit J, Brouwer M, Kuiken CL, Pollakis G, Schuitemaker H, Fontanet AL, Rinke de Wit TF (1999). HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS 13: 1305–1311.
Alexander CS, Montessori V, Wynhoven B, Dong W, Chan K, O’Shaughnessy MV, Mo T, Piaseczny M, Montaner JS, Harrigan PR (2002). Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia. Antivir Ther 7: 31–35.
Bangham CR (1993). Retrovirus infections of the nervous system. Curr Opin Neurol Neurosurg 6: 176–181.
Behnisch T, Francesconi W, Sanna PP (2004). HIV secreted protein Tat prevents long-term potentiation in the hippocampal CA1 region. Brain Res 1012: 187–189.
Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, Albert J, Scarlatti G, Littman DR, Fenyo EM (1997). Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 71: 7478–7487.
Bocket L, Cheret A, Deuffic-Burban S, Choisy P, Gerard Y, de la Tribonniere X, Viget N, Ajana F, Goffard A, Barin F, Mouton Y, Yazdanpanah Y (2005). Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antivir Ther 10: 247–254.
Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, Tsay J, Ip J, Farthing C, Limoli K, Parkin N, Markowitz M (1999). HIV-1 drug resistance in newly infected individuals. JAMA 282: 1135–1141.
Brennan CA, Yamaguchi J, Vallari AS, Hickman RK, Devare SG (1997). Genetic variation in human immunodeficiency virus type 2: identification of a unique variant from human plasma. AIDS Res Hum Retroviruses 13: 401–404.
Brodine SK, Shaffer RA, Starkey MJ, Tasker SA, Gilcrest JL, Louder MK, Barile A, VanCott TC, Vahey MT, McCutchan FE, Birx DL, Richman DD, Mascola JR (1999). Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med 131: 502–506.
Cao Y, Qin L, Zhang L, Safrit J, Ho DD (1995). Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 332: 201–208.
Clavel F, Guyader M, Guetard D, Salle M, Montagnier L, Alizon M (1986). Molecular cloning and polymorphism of the human immune deficiency virus type 2. Nature 324: 691–695.
Clements JE, Babas T, Mankowski JL, Suryanarayana K, Piatak M Jr, Tarwater PM, Lifson JD, Zink MC (2002). The central nervous system as a reservoir for simian immunodeficiency virus (SIV): steady-state levels of SIV DNA in brain from acute through asymptomatic infection. J Infect Dis 186: 905–913.
Costello C, Nelson KE, Suriyanon V, Sennun S, Tovanabutra S, Heilig CM, Shiboski S, Jamieson DJ, Robison V, Rungruenthanakit K, Duerr A (2005). HIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival. Int J Epidemiol 34: 577–584.
Damond F, Apetrei C, Robertson DL, Souquiere S, Lepretre A, Matheron S, Plantier JC, Brun-Vezinet F, Simon F (2001). Variability of human immunodeficiency virus type 2 (HIV-2) infecting patients living in france. Virology 280: 19–30.
Davis LE, Hjelle BL, Miller VE, Palmer DL, Llewellyn AL, Merlin TL, Young SA, Mills RG, Wachsman W, Wiley CA (1992). Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 42: 1736–1739.
De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J (1992). Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 66: 6777–6780.
De Wit S, Boulme R, Poll B, Schmit JC, Clumeck N (2004). Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients. AIDS 18: 2330–2331.
De Wolf F, Hogervorst E, Goudsmit J, Fenyo EM, Rubsamen-Waigmann H, Holmes H, Galvao-Castro B, Karita E, Wasi C, Sempala SD, et al. (1994). Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses 10: 1387–1400.
Descamps D, Collin G, Letourneur F, Apetrei C, Damond F, Loussert-Ajaka I, Simon F, Saragosti S, Brun-Vezinet F (1997). Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol 71: 8893–8898.
Descamps D, Collin G, Loussert-Ajaka I, Saragosti S, Simon F, Brun-Vezinet F (1995). HIV-1 group O sensitivity to antiretroviral drugs. AIDS 9: 977–978.
Donnelly C, Leisenring W, Kanki P, Awerbuch T, Sandberg S (1993). Comparison of transmission rates of HIV-1 and HIV-2 in a cohort of prostitutes in Senegal. Bull Math Biol 55: 731–743.
Dreyer EB, Kaiser PK, Offermann JT, Lipton SA (1990). HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. Science 248: 364–367.
Englund G, Theodore TS, Freed EO, Engelman A, Martin MA (1995). Integration is required for productive infection of monocyte-derived macrophages by human immunodeficiency virus type 1. J Virol 69: 3216–3219.
Epstein LG, Gendelman HE (1993). Human immunodeficiency virus type 1 infection of the nervous system: pathogenetic mechanisms. Ann Neurol 33: 429–436.
Eshleman SH, Becker-Pergola G, Deseyve M, Guay LA, Mracna M, Fleming T, Cunningham S, Musoke P, Mmiro F, Jackson JB (2001). Impact of human immunodeficiency virus type 1 (HIV-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent HIV-1 vertical transmission (HIV Network for Prevention Trials 012 study). J Infect Dis 184: 914–917.
Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, Cummins LB, Arthur LO, Peeters M, Shaw GM, Sharp PM, Hahn BH (1999). Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397: 436–441.
Gao F, Morrison SG, Robertson DL, Thornton CL, Craig S, Karlsson G, Sodroski J, Morgado M, Galvao-Castro B, von Briesen H, Beddows S, Weber J, Sharp PM, Shaw GM, Hahn BH (1996). Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. J Virol 70: 1651–1667.
Gao F, Robertson DL, Carruthers CD, Morrison SG, Jian B, Chen Y, Barre-Sinoussi F, Girard M, Srinivasan A, Abimiku AG, Shaw GM, Sharp PM, Hahn BH (1998). A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. J Virol 72: 5680–5698.
Gao F, Vidal N, Li Y, Trask SA, Chen Y, Kostrikis LG, Ho DD, Kim J, Oh MD, Choe K, Salminen M, Robertson DL, Shaw GM, Hahn BH, Peeters M (2001). Evidence of two distinct subsubtypes within the HIV-1 subtype A radiation. AIDS Res Hum Retroviruses 17: 675–688.
Gendelman HE, Genis P, Jett M, Zhai QH, Nottet HS (1994). An experimental model system for HIV-1-induced brain injury. Adv Neuroimmunol 4: 189–193.
Geretti AM (2006). HIV-1 subtypes: epidemiology and significance for HIV management. Curr Opin Infect Dis 19: 1–7.
Glass JD, Fedor H, Wesselingh SL, McArthur JC (1995). Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 38: 755–762.
Grossman Z, Istomin V, Averbuch D, Lorber M, Risenberg K, Levi I, Chowers M, Burke M, Bar Yaacov N, Schapiro JM (2004a). Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS 18: 909–915.
Grossman Z, Paxinos EE, Averbuch D, Maayan S, Parkin NT, Engelhard D, Lorber M, Istomin V, Shaked Y, Mendelson E, Ram D, Petropoulos CJ, Schapiro JM (2004b). Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob Agents Chemother 48: 2159–2165.
Hahn BH, Shaw GM, De Cock KM, Sharp PM (2000). AIDS as a zoonosis: scientific and public health implications. Science 287: 607–614.
Harrington PR, Haas DW, Ritola K, Swanstrom R (2005). Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells. J Virol 79: 7959–7966.
Hemelaar J, Gouws E, Ghys PD, Osmanov S (2006). Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20: W13-W23.
HIV Sequence Database (2006). Los Alamos National Laboratory.
Hsu LY, Subramaniam R, Bacheler L, Paton NI (2005). Characterization of mutations in CRF01AE virus isolates from antiretroviral treatment-naive and -experienced patients in Singapore. J Acquir Immune Defic Syndr 38: 5–13.
Hu DJ, Buve A, Baggs J, van der Groen G, Dondero TJ (1999). What role does HIV-1 subtype play in transmission and pathogenesis? An epidemiological perspective. AIDS 13: 873–881.
Hwang SS, Boyle TJ, Lyerly HK, Cullen BR (1991). Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 253: 71–74.
Ida S, Gatanaga H, Shioda T, Nagai Y, Kobayashi N, Shimada K, Kimura S, Iwamoto A, Oka S (1997). HIV type 1 V3 variation dynamics in vivo: long-term persistence of non-syncytium-inducing genotypes and transient presence of syncytium-inducing genotypes during the course of progressive AIDS. AIDS Res Hum Retroviruses 13: 1597–1609.
Jaffe HW, Schochetman G (1998). Group O human immunodeficiency virus-1 infections. Infect Dis Clin North Am 12: 39–46.
Johnson RT, Glass JD, McArthur JC, Chesebro BW (1996). Quantitation of human immunodeficiency virus in brains of demented and nondemented patients with acquired immunodeficiency syndrome. Ann Neurol 39: 392–395.
Johnston JB, Jiang Y, van Marle G, Mayne MB, Ni W, Holden J, McArthur JC, Power C (2000). Lentivirus infection in the brain induces matrix metalloproteinase expression: role of envelope diversity. J Virol 74: 7211–7220.
Jones M, Olafson K, Del Bigio MR, Peeling J, Nath A (1998). Intraventricular injection of human immunodeficiency virus type 1 (HIV-1) tat protein causes inflammation, gliosis, apoptosis, and ventricular enlargement. J Neuropathol Exp Neurol 57: 563–570.
Kaleebu P, French N, Mahe C, Yirrell D, Watera C, Lyagoba F, Nakiyingi J, Rutebemberwa A, Morgan D, Weber J, Gilks C, Whitworth J (2002). Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis 185: 1244–1250.
Kaleebu P, Nankya IL, Yirrell DL, Shafer LA, Kyosiimire-Lugemwa J, Lule DB, Morgan D, Beddows S, Weber J, Whitworth JA (2007). Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr 2007 May 1; 45(1): 28–33.
Kandathil AJ, Ramalingam S, Kannangai R, David S, Sridharan G (2005). Molecular epidemiology of HIV. Indian J Med Res 121: 333–344.
Kanki PJ, Hamel DJ, Sankale JL, Hsieh C, Thior I, Barin F, Woodcock SA, Gueye-Ndiaye A, Zhang E, Montano M, Siby T, Marlink R, I ND, Essex ME, S MB (1999). Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 179: 68–73.
Kanki PJ, Travers KU, S MB, Hsieh CC, Marlink RG, Gueye NA, Siby T, Thior I, Hernandez-Avila M, Sankale JL, et al. (1994). Slower heterosexual spread of HIV-2 than HIV-1. Lancet 343: 943–946.
Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, Clarke J, Sirivichayakul S, Soares MA, Snoeck J, Pillay C, Rudich H, Rodrigues R, Holguin A, Ariyoshi K, Bouzas MB, Cahn P, Sugiura W, Soriano V, Brigido LF, Grossman Z, Morris L, Vandamme AM, Tanuri A, Phanuphak P, Weber JN, Pillay D, Harrigan PR, Camacho R, Schapiro JM, Shafer RW (2005). Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2: e112.
Kaul M, Lipton SA (1999). Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci U S A 96: 8212–8216.
Keet IP, Krijnen P, Koot M, Lange JM, Miedema F, Goudsmit J, Coutinho RA (1993). Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS 7: 51–57.
Kijak GH, McCutchan FE (2005). HIV diversity, molecular epidemiology, and the role of recombination. Curr Infect Dis Rep 7: 480–488.
Kilmarx PH, Limpakarnjanarat K, Kaewkungwal J, Srismith R, Saisorn S, Uthaivoravit W, Young NL, Mastro TD (2000). Disease progression and survival with human immunodeficiency virus type 1 subtype E infection among female sex workers in Thailand. J Infect Dis 181: 1598–1606.
Kong LY, Wilson BC, McMillian MK, Bing G, Hudson PM, Hong JS (1996). The effects of the HIV-1 envelope protein gp120 on the production of nitric oxide and proinflammatory cytokines in mixed glial cell cultures. Cell Immunol 172: 77–83.
Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, Miedema F, Schellekens PT, Tersmette M (1993). Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 118: 681–688.
Kozak SL, Platt EJ, Madani N, Ferro FE, Jr., Peden K, Kabat D (1997). CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J Virol 71: 873–882.
Kramer-Hammerle S, Rothenaigner I, Wolff H, Bell JE, Brack-Werner R (2005). Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res 111: 194–213.
Kure K, Lyman WD, Weidenheim KM, Dickson DW (1990). Cellular localization of an HIV-1 antigen in subacute AIDS encephalitis using an improved double-labeling immunohistochemical method. Am J Pathol 136: 1085–1092.
Laeyendecker O, Li X, Arroyo M, McCutchan F, et al (2006). The effect of HIV subtype on rapid disease progression in Rakai, Uganda. In: Proceedings, 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO.
Lannuzel A, Lledo PM, Lamghitnia HO, Vincent JD, Tardieu M (1995). HIV-1 envelope proteins gp120 and gp160 potentiate NMDA-induced [Ca2+]i increase, alter [Ca2+]i homeostasis and induce neurotoxicity in human embryonic neurons. Eur J Neurosci 7: 2285–2293.
Lazarini F, Seilhean D, Rosenblum O, Suarez S, Conquy L, Uchihara T, Sazdovitch V, Mokhtari K, Maisonobe T, Boussin F, Katlama C, Bricaire F, Duyckaerts C, Hauw JJ (1997). Human immunodeficiency virus type 1 DNA and RNA load in brains of demented and nondemented patients with acquired immunodeficiency syndrome. J NeuroVirol 3: 299–303.
Levi G, Patrizio M, Bernardo A, Petrucci TC, Agresti C (1993). Human immunodeficiency virus coat protein gp120 inhibits the beta-adrenergic regulation of astroglial and microglial functions. Proc Natl Acad Sci U S A. 90: 1541–1545.
Levy JA (1991). Viral and cellular factors influencing HIV tropism. Adv Exp Med Biol 300: 1–15.
Liesch GR, DeStefano JJ (2003). Analysis of mutations made during active synthesis or extension of mismatched substrates further define the mechanism of HIV-RT mutagenesis. Biochemistry 42: 5925–5936.
Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD (2002). Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347: 385–394.
Littman DR (1998). Chemokine receptors: keys to AIDS pathogenesis? Cell 93: 677–680.
Liu P, Hudson LC, Tompkins MB, Vahlenkamp TW, Colby B, Rundle C, Meeker RB (2006). Cerebrospinal fluid is an efficient route for establishing brain infection with feline immunodeficiency virus and transfering infectious virus to the periphery. J NeuroVirol 12: 294–306.
Loemba H, Brenner B, Parniak MA, Ma’ayan S, Spira B, Moisi D, Oliveira M, Detorio M, Wainberg MA (2002). Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother 46: 2087–2094.
Lynch WP, Czub S, McAtee FJ, Hayes SF, Portis JL (1991). Murine retrovirus-induced spongiform encephalopathy: productive infection of microglia and cerebellar neurons in accelerated CNS disease. Neuron 7: 365–379.
Maniar JK, Damond F, Kamath RR, Mandalia S, Surjushe A (2006). Antiretroviral drug-resistant HIV-2 infection—a new therapeutic dilemma. Int J STD AIDS 17: 781–782.
Mankowski JL, Flaherty MT, Spelman JP, Hauer DA, Didier PJ, Amedee AM, Murphey-Corb M, Kirstein LM, Munoz A, Clements JE, Zink MC (1997). Pathogenesis of simian immunodeficiency virus encephalitis: viral determinants of neurovirulence. J Virol 71: 6055–6060.
Maragos WF, Tillman P, Jones M, Bruce-Keller AJ, Roth S, Bell JE, Nath A (2003). Neuronal injury in hippocampus with human immunodeficiency virus transactivating protein, Tat. Neuroscience 117: 43–53.
Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, Traore I, Hsieh CC, Dia MC, Gueye EH, et al. (1994). Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 265: 1587–1590.
Masliah E, Ge N, Achim CL, Hansen LA, Wiley CA (1992). Selective neuronal vulnerability in HIV encephalitis. J Neuropathol Exp Neurol 51: 585–593.
Masliah E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, Mallory M, Achim CL, McCutchan JA, Nelson JA, Atkinson JH, Grant I (1997). Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol 42: 963–972.
Mattson MP, Haughey NJ, Nath A (2005). Cell death in HIV dementia. Cell Death Differ 12(Suppl 1): 893–904.
McArthur JC, McDermott MP, McClernon D, St Hillaire C, Conant K, Marder K, Schifitto G, Selnes OA, Sacktor N, Stern Y, Albert SM, Kieburtz K, deMarcaida JA, Cohen B, Epstein LG (2004). Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol 61: 1687–1696.
McCutchan FE (2006). Global epidemiology of HIV. J Med Virol 78(Suppl 1): S7-S12.
Mehendale SM, Bollinger RC, Kulkarni SS, Stallings RY, Brookmeyer RS, Kulkarni SV, Divekar AD, Gangakhedkar RR, Joshi SN, Risbud AR, Thakar MA, Mahajan BA, Kale VA, Ghate MV, Gadkari DA, Quinn TC, Paranjape RS (2002). Rapid disease progression in human immunodeficiency virus type 1-infected sero-converters in India. AIDS Res Hum Retroviruses 18: 1175–1179.
Mendez I, Swanson M, Coombs K. (2003). Introduction to Virus Structure, Classification, Replication, and Hosts. In: Clinical neurovirology. Nath A, Berger J (eds). New York: Marcel Dekker, p 634.
Merrill JE, Koyanagi Y, Zack J, Thomas L, Martin F, Chen IS (1992). Induction of interleukin-1 and tumor necrosis factor alpha in brain cultures by human immunodeficiency virus type 1. J Virol 66: 2217–2225.
Mollace V, Colasanti M, Persichini T, Bagetta G, Lauro GM, Nistico G (1993). HIV gp120 glycoprotein stimulates the inducible isoform of no synthase in human cultured astrocytoma cells. Biochem Biophys Res Commun 194: 439–445.
Morris A, Marsden M, Halcrow K, Hughes ES, Brettle RP, Bell JE, Simmonds P (1999). Mosaic structure of the human immunodeficiency virus type 1 genome infecting lymphoid cells and the brain: evidence for frequent in vivo recombination events in the evolution of regional populations. J Virol 73: 8720–8731.
Nath A, Conant K, Chen P, Scott C, Major EO (1999). Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon. J Biol Chem 274: 17098–17102.
Nielsen C, Pedersen C, Lundgren JD, Gerstoft J (1993). Biological properties of HIV isolates in primary HIV infection: consequences for the subsequent course of infection. AIDS 7: 1035–1040.
Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M, Moser B (1996). The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 382: 833–835.
Ohagen A, Ghosh S, He J, Huang K, Chen Y, Yuan M, Osathanondh R, Gartner S, Shi B, Shaw G, Gabuzda D (1999). Apoptosis induced by infection of primary brain cultures with diverse human immunodeficiency virus type 1 isolates: evidence for a role of the envelope. J Virol 73: 897–906.
Palmer S, Alaeus A, Albert J, Cox S (1998). Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses 14: 157–162.
Patton HK, Zhou ZH, Bubien JK, Benveniste EN, Benos DJ (2000). gp120-induced alterations of human astrocyte function: Na(+)/H(+) exchange, K(+) conductance, and glutamate flux. Am J Physiol Cell Physiol 279: C700-C708.
Peeters M, Vincent R, Perret JL, Lasky M, Patrel D, Liegeois F, Courgnaud V, Seng R, Matton T, Molinier S, Delaporte E (1999). Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retrovirol 20: 115–121.
Philippon V, Vellutini C, Gambarelli D, Harkiss G, Arbuthnott G, Metzger D, Roubin R, Filippi P (1994). The basic domain of the lentiviral Tat protein is responsible for damages in mouse brain: involvement of cytokines. Virology 205: 519–529.
Pieniazek D, Ellenberger D, Janini LM, Ramos AC, Nkengasong J, Sassan-Morokro M, Hu DJ, Coulibally IM, Ekpini E, Bandea C, Tanuri A, Greenberg AE, Wiktor SZ, Rayfield MA (1999). Predominance of human immunodeficiency virus type 2 subtype B in Abidjan, Ivory Coast. AIDS Res Hum Retroviruses 15: 603–608.
Pillay D, Walker AS, Gibb DM, de Rossi A, Kaye S, Ait-Khaled M, Munoz-Fernandez M, Babiker A (2002). Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J Infect Dis 186: 617–625.
Ping LH, Nelson JA, Hoffman IF, Schock J, Lamers SL, Goodman M, Vernazza P, Kazembe P, Maida M, Zimba D, Goodenow MM, Eron JJ Jr, Fiscus SA, Cohen MS, Swanstrom R (1999). Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J Virol 73: 6271–6281.
Power C, McArthur JC, Johnson RT, Griffin DE, Glass JD, Perryman S, Chesebro B (1994). Demented and non-demented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol 68: 4643–4649.
Power C, McArthur JC, Nath A, Wehrly K, Mayne M, Nishio J, Langelier T, Johnson RT, Chesebro B (1998). Neuronal death induced by brain-derived human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patients. J Virol 72: 9045–9053.
Power C, Zhang K, van Marle G (2004). Comparative neurovirulence in lentiviral infections: The roles of viral molecular diversity and select proteases. J NeuroVirol 10(Suppl 1): 113–117.
Preston BD, Poiesz BJ, Loeb LA (1988). Fidelity of HIV-1 reverse transcriptase. Science 242: 1168–1171.
Reeves JD, Doms RW (2002). Human immunodeficiency virus type 2. J Gen Virol 83: 1253–1265.
Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK (2002). Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci U S A 99: 14410–14415.
Ritola K, Robertson K, Fiscus SA, Hall C, Swanstrom R (2005). Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol 79: 10830–10834.
Roberts JD, Bebenek K, Kunkel TA (1988). The accuracy of reverse transcriptase from HIV-1. Science 242: 1171–1173.
Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, Funkhouser RK, Gao F, Hahn BH, Kalish ML, Kuiken C, Learn GH, Leitner T, McCutchan F, Osmanov S, Peeters M, Pieniazek D, Salminen M, Sharp PM, Wolinsky S, Korber B (2000). HIV-1 nomenclature proposal. Science 288: 55–56.
Rodes B, Toro C, Paxinos E, Poveda E, Martinez-Padial M, Benito JM, Jimenez V, Wrin T, Bassani S, Soriano V (2004). Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection. AIDS 18: 1109–1116.
Sevigny JJ, Albert SM, McDermott MP, McArthur JC, Sacktor N, Conant K, Schifitto G, Selnes OA, Stern Y, McClernon DR, Palumbo D, Kieburtz K, Riggs G, Cohen B, Epstein LG, Marder K (2004). Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 63: 2084–2090.
Sharp PM, Robertson DL, Hahn BH (1995). Cross-species transmission and recombination of ‘AIDS’ viruses. Philos Trans R Soc Lond B Biol Sci 349: 41–47.
Simon F, Mauclere P, Roques P, Loussert-Ajaka I, Muller-Trutwin MC, Saragosti S, Georges-Courbot MC, Barre-Sinoussi F, Brun-Vezinet F (1998). Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med 4: 1032–1037.
Simon V, Ho DD (2003). HIV-1 dynamics in vivo: implications for therapy. Nat Rev Microbiol 1: 181–190.
Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, Dawson K, Parkin N, Boden D, Markowitz M (2002). Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 16: 1511–1519.
Smit TK, Brew BJ, Tourtellotte W, Morgello S, Gelman BB, Saksena NK (2004). Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol 78: 10133–10148.
Soriano V, Gomes P, Heneine W, Holguin A, Doruana M, Antunes R, Mansinho K, Switzer WM, Araujo C, Shanmugam V, Lourenco H, Gonzalez-Lahoz J, Antunes F (2000). Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. J Med Virol 61: 111–116.
Soto-Ramirez LE, Renjifo B, McLane MF, Marlink R, O’Hara C, Sutthent R, Wasi C, Vithayasai P, Vithayasai V, Apichartpiyakul C, Auewarakul P, Pena Cruz V, Chui DS, Osathanondh R, Mayer K, Lee TH, Essex M (1996). HIV-1 Langerhans’ cell tropism associated with heterosexual transmission of HIV. Science 271: 1291–1293.
Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG (2003). Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 51: 229–240.
Stevenson M, Haggerty S, Lamonica CA, Meier CM, Welch SK, Wasiak AJ (1990). Integration is not necessary for expression of human immunodeficiency virus type 1 protein products. J Virol 64: 2421–2425.
Takahashi K, Wesselingh SL, Griffin DE, McArthur JC, Johnson RT, Glass JD (1996). Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Ann Neurol 39: 705–711.
Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, Pauwels R, Andries K, Janssen PA, Arnold E (1994). Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol 243: 369–387.
Teo I, Veryard C, Barnes H, An SF, Jones M, Lantos PL, Luthert P, Shaunak S (1997). Circular forms of unintegrated human immunodeficiency virus type 1 DNA and high levels of viral protein expression: association with dementia and multinucleated giant cells in the brains of patients with AIDS. J Virol 71: 2928–2933.
Tersmette M, de Goede RE, Al BJ, Winkel IN, Gruters RA, Cuypers HT, Huisman HG, Miedema F (1988). Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 62: 2026–2032.
Thomson MM, Perez-Alvarez L, Najera R (2002). Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis 2: 461–471.
Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L (1994). Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 367: 188–193.
Trillo-Pazos G, Diamanturos A, Rislove L, Menza T, Chao W, Belem P, Sadiq S, Morgello S, Sharer L, Volsky DJ (2003). Detection of HIV-1 DNA in microglia/macrophages, astrocytes and neurons isolated from brain tissue with HIV-1 encephalitis by laser capture microdissection. Brain Pathol 13: 144–154.
Tscherning C, Alaeus A, Fredriksson R, Bjorndal A, Deng H, Littman DR, Fenyo EM, Albert J (1998). Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 241: 181–188.
Vasan A, Renjifo B, Hertzmark E, Chaplin B, Msamanga G, Essex M, Fawzi W, Hunter D (2006). Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 42: 843–852.
Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, Mboup S, Mulanga-Kabeya C, Saman E, Jourdan J, Reynes J, Delaporte E (2000). Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 38: 3919–3925.
Vidal N, Peeters M, Mulanga-Kabeya C, Nzilambi N, Robertson D, Ilunga W, Sema H, Tshimanga K, Bongo B, Delaporte E (2000). Unprecedented degree of human immunodeficiency virus type 1 (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa. J Virol 74: 10498–10507.
Wiskerchen M, Muesing MA (1995). Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells. J Virol 69: 376–386.
Yang C, Li M, Mokili JL, Winter J, Lubaki NM, Mwandagalirwa KM, Kasali MJ, Losoma AJ, Quinn TC, Bollinger RC, Lal RB (2005). Genetic diversification and recombination of HIV type 1 group M in Kinshasa, Democratic Republic of Congo. AIDS Res Hum Retroviruses 21: 661–666.
Yang G, Song Q, Charles M, Drosopoulos WC, Arnold E, Prasad VR (1996). Use of chimeric human immunodeficiency virus types 1 and 2 reverse transcriptases for structure-function analysis and for mapping susceptibility to nonnucleoside inhibitors. J Acquir Immune Defic SyndrHum Retrovirol 11: 326–333.
Yepthomi T, Paul R, Vallabhaneni S, Kumarasamy N, Tate DF, Solomon S, Flanigan T (2006). Neurocognitive consequences of HIV in southern India: a preliminary study of clade C virus. J Int Neuropsychol Soc 12: 424–430.
Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L (1999). Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 354: 729–733.
Yeung MC, Pulliam L, Lau AS (1995). The HIV envelope protein gp120 is toxic to human brain-cell cultures through the induction of interleukin-6 and tumor necrosis factor-alpha. AIDS 9: 137–143.
Zekeng L, Gurtler L, Afane Ze E, Sam-Abbenyi A, Mbouni-Essomba G, Mpoudi-Ngolle E, Monny-Lobe M, Tapka JB, Kaptue L (1994). Prevalence of HIV-1 subtype O infection in Cameroon: preliminary results. AIDS 8: 1626–1628.
Zhang K, Hawken M, Rana F, Welte FJ, Gartner S, Goldsmith MA, Power C (2001). Human immunodeficiency virus type 1 clade A and D neurotropism: molecular evolution, recombination, and coreceptor use. Virology 283: 19–30.
Zhang K, Rana F, Silva C, Ethier J, Wehrly K, Chesebro B, Power C (2003). Human immunodeficiency virus type 1 envelope-mediated neuronal death: uncoupling of viral replication and neurotoxicity. J Virol 77: 6899–6912.
Zhang L, Huang Y, He T, Cao Y, Ho DD (1996). HIV-1 subtype and second-receptor use. Nature 383: 768.
Zhao ML, Kim MO, Morgello S, Lee SC (2001). Expression of inducible nitric oxide synthase, interleukin-1 and caspase-1 in HIV-1 encephalitis. J Neuroimmunol 115: 182–191.
Zhong P, Peeters M, Janssens W, Fransen K, Heyndrickx L, Vanham G, Willems B, Piot P, van der Groen G (1995). Correlation between genetic and biological properties of biologically cloned HIV type 1 viruses representing subtypes A, B, and D. AIDS Res Hum Retroviruses 11: 239–248.
Zink MC, Clements JE (2002). A novel simian immunodeficiency virus model that provides insight into mechanisms of human immunodeficiency virus central nervous system disease. J NeuroVirol 8(Suppl 2): 42–48.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liner, K.J., Hall, C.D. & Robertson, K.R. Impact of human immunodeficiency virus (HIV) subtypes on HIV-associated neurological disease. Journal of NeuroVirology 13, 291–304 (2007). https://doi.org/10.1080/13550280701422383
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1080/13550280701422383